Dimerix (ASX:DXB) said the results of an analysis by Parasol are consistent with the analysis conducted last year that supported the use of proteinuria as a clinical trial endpoint for focal segmental glomerulosclerosis, a kidney disease, according to a Wednesday filing with the Australian bourse.

The company said the results cannot be disclosed as they are subject to commercial-in-confidence restrictions.

The company, along with its US partner Amicus Therapeutics, intends to seek feedback from the US Food and Drug Administration on the new findings in the coming months, the filing said.

Shares of the company rose 7% in recent Wednesday trade.